Continued here: Umoja Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Continued here: Umoja Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Go here to read the rest: Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Read this article: Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
See more here: Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering
Link: Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
Visit link: Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide
Read more from the original source: Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
See the original post: Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
View post: Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe
Go here to see the original: Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
Recent Comments